259 related articles for article (PubMed ID: 15365146)
1. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Triebels VH; Taphoorn MJ; Brandes AA; Menten J; Frenay M; Tosoni A; Kros JM; Stege EB; Enting RH; Allgeier A; van Heuvel I; van den Bent MJ
Neurology; 2004 Sep; 63(5):904-6. PubMed ID: 15365146
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B
Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108
[TBL] [Abstract][Full Text] [Related]
3. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
5. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Levin VA
Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
[No Abstract] [Full Text] [Related]
6. Initial chemotherapy in gliomatosis cerebri.
Sanson M; Cartalat-Carel S; Taillibert S; Napolitano M; Djafari L; Cougnard J; Gervais H; Laigle F; Carpentier A; Mokhtari K; Taillandier L; Chinot O; Duffau H; Honnorat J; Hoang-Xuan K; Delattre JY;
Neurology; 2004 Jul; 63(2):270-5. PubMed ID: 15277619
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R
J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516
[TBL] [Abstract][Full Text] [Related]
8. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Rinne ML; Wen PY
Oncology (Williston Park); 2015 Apr; 29(4):265, 275. PubMed ID: 25952491
[No Abstract] [Full Text] [Related]
9. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
[TBL] [Abstract][Full Text] [Related]
11. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for the treatment of oligodendroglial tumors.
Chinot O
Semin Oncol; 2001 Aug; 28(4 Suppl 13):13-8. PubMed ID: 11550134
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
[TBL] [Abstract][Full Text] [Related]
15. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Chinot OL; Honore S; Dufour H; Barrie M; Figarella-Branger D; Muracciole X; Braguer D; Martin PM; Grisoli F
J Clin Oncol; 2001 May; 19(9):2449-55. PubMed ID: 11331324
[TBL] [Abstract][Full Text] [Related]
17. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.
Chahlavi A; Kanner A; Peereboom D; Staugaitis SM; Elson P; Barnett G
J Neurooncol; 2003 Feb; 61(3):267-73. PubMed ID: 12675321
[TBL] [Abstract][Full Text] [Related]
18. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.
Streffer J; Schabet M; Bamberg M; Grote EH; Meyermann R; Voigt K; Dichgans J; Weller M
J Neurol; 2000 Apr; 247(4):297-302. PubMed ID: 10836623
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
Gonzalez-Aguilar A; Reyes-Moreno I; Peiro-Osuna RP; Hernandez-Hernandez A; Gutierrez-Aceves A; Santos-Zambrano J; Guerrero-Juarez V; Lopez-Martinez M; Castro-Martinez E
Rev Neurol; 2018 Oct; 67(8):293-297. PubMed ID: 30289152
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Vogelbaum MA; Berkey B; Peereboom D; Macdonald D; Giannini C; Suh JH; Jenkins R; Herman J; Brown P; Blumenthal DT; Biggs C; Schultz C; Mehta M
Neuro Oncol; 2009 Apr; 11(2):167-75. PubMed ID: 18779504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
